Doug Wilson

A precision therapy against cancers driven by <i>KIT/PDGFRA</i> mutations

Erica Evans, Alexandra K. Gardino, Joseph L. Kim et al. · Science Translational Medicine · 2017 · 214 citations

Medicine, Oncology, Pharmacology +10

Combination of EP ₄ antagonist MF-766 and anti-PD-1 promotes anti-tumor efficacy by modulating both lymphocytes and myeloid cells

Yun Wang, Long Cui, Peter Georgiev et al. · OncoImmunology · 2021 · 49 citations · Full text

Medicine, Immunology, Pharmacology +17

Abstract 791: BLU-285, the first selective inhibitor of PDGFRα D842V and KIT Exon 17 mutants

Erica Evans, Brian L. Hodous, Alexandra K. Gardino et al. · Cancer Research · 2015 · 23 citations

Medicine, Oncology, Pharmacology +14

First Selective KIT D816V Inhibitor for Patients with Systemic Mastocytosis

Erica Evans, Brian L. Hodous, Alexandra K. Gardino et al. · Blood · 2014 · 19 citations

Life Sciences, Immunology, Pharmacotherapy +10

Abstract 1467: BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with intracranial activity, demonstrates robust <i>in vivo</i> antitumor activity in models of osimertinib-resistant non-small cell lung cancer (NSCLC)

Sun Min Lim, Chae Won Park, Zhuo Zhang et al. · Cancer Research · 2021 · 19 citations

Medicine, Oncology, Pharmacology +17